JP3524061B2 - 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法 - Google Patents
肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法Info
- Publication number
- JP3524061B2 JP3524061B2 JP2000563828A JP2000563828A JP3524061B2 JP 3524061 B2 JP3524061 B2 JP 3524061B2 JP 2000563828 A JP2000563828 A JP 2000563828A JP 2000563828 A JP2000563828 A JP 2000563828A JP 3524061 B2 JP3524061 B2 JP 3524061B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lsg
- lung cancer
- tissue
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims description 54
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 53
- 201000005202 lung cancer Diseases 0.000 title claims description 53
- 238000000034 method Methods 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 210000001124 body fluid Anatomy 0.000 claims description 37
- 239000010839 body fluid Substances 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 230000005298 paramagnetic effect Effects 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 82
- 206010028980 Neoplasm Diseases 0.000 description 73
- 201000011510 cancer Diseases 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 46
- 239000000523 sample Substances 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 25
- 210000004072 lung Anatomy 0.000 description 24
- 238000012544 monitoring process Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 238000007685 laparoscopic sleeve gastrectomy Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 206010050017 Lung cancer metastatic Diseases 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 206010041067 Small cell lung cancer Diseases 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- 102100037611 Lysophospholipase Human genes 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 108010058864 Phospholipases A2 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 206010027406 Mesothelioma Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940055742 indium-111 Drugs 0.000 description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001216 nucleic acid method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063599 Exposure to chemical pollution Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000003103 bodily secretion Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9523398P | 1998-08-04 | 1998-08-04 | |
| US60/095,233 | 1998-08-04 | ||
| PCT/US1999/016247 WO2000008206A1 (en) | 1998-08-04 | 1999-07-19 | A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002522046A JP2002522046A (ja) | 2002-07-23 |
| JP3524061B2 true JP3524061B2 (ja) | 2004-04-26 |
Family
ID=22250833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563828A Expired - Fee Related JP3524061B2 (ja) | 1998-08-04 | 1999-07-19 | 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1104486A4 (de) |
| JP (1) | JP3524061B2 (de) |
| CA (1) | CA2347656A1 (de) |
| WO (1) | WO2000008206A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869592B1 (en) | 1998-08-04 | 2005-03-22 | Diadexus, Inc. | Method and antibody for imaging lung cancer |
| WO2002018576A2 (en) * | 2000-08-28 | 2002-03-07 | Diadexus, Inc. | Compositions and methods relating to lung specific genes |
| JP2004520821A (ja) * | 2000-10-26 | 2004-07-15 | ディアデクサス インコーポレーテッド | 肺特異的遺伝子およびタンパク質に関する組成物および方法 |
| EP1392829A2 (de) * | 2000-11-20 | 2004-03-03 | Diadexus, Inc. | Zusammensetzungen und verfahren mit bezug zu lungen-spezifischen genen und proteinen |
| EP1346043A2 (de) * | 2000-11-20 | 2003-09-24 | Diadexus, Inc. | Zusammensetzungen und verfahren in verbindung mit lungenspezifischen genen und proteinen |
| WO2002068633A2 (en) * | 2000-11-22 | 2002-09-06 | Diadexus, Inc. | Compositions and methods relating to lung specific genes and proteins |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (de) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs |
| US7951781B2 (en) | 2006-11-02 | 2011-05-31 | University Of Iowa Research Foundation | Methods and compositions related to PLUNC surfactant polypeptides |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589579A (en) * | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
| EP0695760A1 (de) * | 1994-08-05 | 1996-02-07 | F. Hoffmann-La Roche Ag | Tumormarker für Lungenkrebs |
| WO1998020143A1 (en) * | 1996-11-05 | 1998-05-14 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the lung |
| JP2001526546A (ja) * | 1997-06-11 | 2001-12-18 | アボツト・ラボラトリーズ | 肺の疾患の検出に有用な試薬および方法 |
| JP3688585B2 (ja) * | 1998-05-21 | 2005-08-31 | ダイアデクスアス・インコーポレーテッド | 肺癌を診断し、モニターし、そして病期決定する新規方法 |
-
1999
- 1999-07-19 WO PCT/US1999/016247 patent/WO2000008206A1/en not_active Application Discontinuation
- 1999-07-19 EP EP99935685A patent/EP1104486A4/de not_active Withdrawn
- 1999-07-19 CA CA002347656A patent/CA2347656A1/en not_active Abandoned
- 1999-07-19 JP JP2000563828A patent/JP3524061B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1104486A4 (de) | 2002-07-17 |
| WO2000008206A1 (en) | 2000-02-17 |
| CA2347656A1 (en) | 2000-02-17 |
| JP2002522046A (ja) | 2002-07-23 |
| EP1104486A1 (de) | 2001-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3422776B2 (ja) | 乳癌を診断、監視、病期決定、造影及び治療する新規な方法 | |
| US7858325B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| US7737255B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating various cancers | |
| US20050266483A1 (en) | Novel method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| WO1999060160A1 (en) | A novel method of diagnosing, monitoring, and staging lung cancer | |
| JP3524061B2 (ja) | 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法 | |
| JP2002527758A (ja) | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 | |
| JP2003526342A (ja) | 乳癌の診断、モニタニング、ステージング、イメージングおよび処置の新規方法 | |
| JP2002526760A (ja) | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
| JP2002527757A (ja) | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 | |
| US6858386B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| US6869592B1 (en) | Method and antibody for imaging lung cancer | |
| JP2002526055A (ja) | 婦人科癌及び精巣癌を診断、監視、病期分類、イメージング及び治療する方法 | |
| US7326402B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating cancer | |
| JP3524536B2 (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 | |
| US7160679B1 (en) | Method of diagnosing, monitoring, and staging lung cancer | |
| JP2002527723A (ja) | 婦人科癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
| JP2002526752A (ja) | 婦人科がんおよび前立腺がんの診断、モニタリング、病期分類および治療の新規方法 | |
| JP2003515145A (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031210 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040210 |
|
| LAPS | Cancellation because of no payment of annual fees |